The sum was factored into the company’s sales and earnings outlook for the year, he said. Meanwhile, Pfizer expanded its ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

Pfizer’s pipeline is robust, with RSV vaccine expansions and AI-driven R&D enhancing long-term prospects. Cost-cutting measures, including manufacturing optimization, improved adjusted gross ...

Pfizer said today it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research ...

Pfizer’s Irish staff face an anxious wait after the company said it was seeking another €1.5bn in annual cost savings globally on top of €5.3 billion previously announced over the past two ...

Pfizer delivered stronger-than-expected earnings for Q1 2025, posting an adjusted diluted EPS of $0.92, significantly above analysts’ expectations of $0.60. The earnings beat wa ...

Pfizer on Tuesday reaffirmed its outlook for ... The company launched its multiyear cost-cutting plan in 2023 after the drugmaker miscalculated demand for its Covid-19 products.